Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Scientists Discover a New Potential Treatment Target for High Blood Pressure (opens in a new tab)

scitechdaily.com · 2026-09-26

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Three of four claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 3 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredThe study focused on female mice, and the article says future research could examine whether the effects differ by sex.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the in vivo study used female mice only. However, the specific claim that the article says future research could examine sex differences is not directly verifiable from the supplied abstract-depth paper profile, although it is a reasonable implication of the female-only limitation.

1

Study evidence

Myeloid-specific TG2 deletion (MyTG2KO) markedly reduced angiotensin II–induced increases in systolic blood pressure, aortic stiffness, and vascular collagen deposition relative to littermate controls after 14 days of Ang II infusion.

“Female mice with myeloid-specific deletion of TG2 (MyTG2KO) and littermate controls were infused with Ang II for 14 days.”
2

Study evidence

Myeloid TG2 deletion lowered vascular expression of proinflammatory markers and circulating cytokines in Ang II–infused female mice.markedly reduced (as reported in abstract)

“Deleting myeloid TG2 lowered vascular expression of proinflammatory markers and circulating cytokines.”
Claim 2 of 4SupportedResearchers at the University of Missouri are investigating whether a protein called TG2, found in blood vessels and certain immune cells, could offer a new target for treatment of high blood pressure.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the study investigates myeloid-cell TG2 in Ang II-induced hypertension/aortic stiffening and inflammation, and it notes TG2 is implicated in vascular and immune-cell biology. The treatment-target framing is speculative and appropriately hedged; the paper profile likewise says authors propose targeting myeloid TG2 as a possible strategy, not an established treatment.

1

Study evidence

Myeloid-specific TG2 deletion (MyTG2KO) markedly reduced angiotensin II–induced increases in systolic blood pressure, aortic stiffness, and vascular collagen deposition relative to littermate controls after 14 days of Ang II infusion.

“Female mice with myeloid-specific deletion of TG2 (MyTG2KO) and littermate controls were infused with Ang II for 14 days.”
2

Study evidence

Myeloid TG2 deletion lowered vascular expression of proinflammatory markers and circulating cytokines in Ang II–infused female mice.markedly reduced (as reported in abstract)

“Deleting myeloid TG2 lowered vascular expression of proinflammatory markers and circulating cytokines.”
Claim 3 of 4SupportedIn a study of female mice, removing TG2 from immune cells reduced the rise in blood pressure, arterial stiffness, and inflammation triggered by angiotensin II.View evidenceHide evidence

As statedreduced the rise in blood pressure, arterial stiffness, and inflammation

Why this verdict

Supported at abstract depth. The profile reports female myeloid-specific TG2 knockout mice and littermate controls infused with Ang II for 14 days; myeloid TG2 deletion markedly reduced Ang II-induced systolic blood pressure, aortic stiffness, vascular collagen deposition, vascular proinflammatory markers, circulating cytokines, and immune-balance disruption. The story’s wording 'immune cells' is slightly broader than the paper’s 'myeloid cells,' but the summary elsewhere specifies myeloid immune cells and the central claim matches the evidence.

1

Study evidence

Myeloid-specific TG2 deletion (MyTG2KO) markedly reduced angiotensin II–induced increases in systolic blood pressure, aortic stiffness, and vascular collagen deposition relative to littermate controls after 14 days of Ang II infusion.

“Female mice with myeloid-specific deletion of TG2 (MyTG2KO) and littermate controls were infused with Ang II for 14 days.”
2

Study evidence

Myeloid TG2 deletion lowered vascular expression of proinflammatory markers and circulating cytokines in Ang II–infused female mice.markedly reduced (as reported in abstract)

“Deleting myeloid TG2 lowered vascular expression of proinflammatory markers and circulating cytokines.”
Claim 4 of 4SupportedThe findings suggest that targeting TG2 could help address inflammation that contributes to high blood pressure, but whether blocking that activity can safely and effectively treat people remains to be established.View evidenceHide evidence

Why this verdict

The speculative framing is consistent with the paper profile: the authors present myeloid TG2 as contributing to Ang II-related immune imbalance, vascular inflammation, aortic stiffening, and hypertension, and propose targeting TG2 in myeloid cells as a possible strategy. The caveat that safe and effective treatment in people remains unproven is appropriate because the evidence summarized is from female mice and in vitro/ex vivo coculture work, not human treatment studies.

1

Study evidence

Myeloid-specific TG2 deletion (MyTG2KO) markedly reduced angiotensin II–induced increases in systolic blood pressure, aortic stiffness, and vascular collagen deposition relative to littermate controls after 14 days of Ang II infusion.

“Female mice with myeloid-specific deletion of TG2 (MyTG2KO) and littermate controls were infused with Ang II for 14 days.”
2

Study evidence

Myeloid TG2 deletion lowered vascular expression of proinflammatory markers and circulating cytokines in Ang II–infused female mice.markedly reduced (as reported in abstract)

“Deleting myeloid TG2 lowered vascular expression of proinflammatory markers and circulating cytokines.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Myeloid TG2 deletion also reduced vascular collagen deposition/remodeling in the Ang II model.

    Vascular collagen deposition/remodeling is a reported primary vascular-remodeling outcome in the profile, but the story’s claims mention blood pressure, arterial stiffness, and inflammation rather than collagen deposition or remodeling.

    From in_vivo_conditional_knockout

  • Ang II disrupted immune balance in controls by decreasing Tregs and increasing Th17 cells, and these shifts were attenuated in MyTG2KO mice.

    The story mentions inflammation generally but does not describe the Treg/Th17 immune-balance findings, which are a material mechanistic element of the paper profile.

    From In vivo Ang II infusion in female myeloid-specific TG2 conditional knockout vs littermate controls; flow cytometry and i

  • Coculture experiments with TG2-deficient macrophages promoted Treg development, suppressed Th17 polarization, and decreased CD8+ T cell cytotoxicity.

    The story does not discuss the in vitro/ex vivo macrophage–T cell coculture experiments or the specific T cell differentiation/function results.

    From in vitro macrophage–T cell coculture

  • The study’s in vivo scope is limited to a 14-day Ang II infusion paradigm; longer-term effects and other hypertension models are not established at abstract depth.

    The story does not mention the short intervention duration or the limitation that longer-term effects are not reported in the abstract-level profile.

    From in_vivo_conditional_knockout; In vivo Ang II infusion in female myeloid-specific TG2 conditional knockout vs littermate

4 things the story did carry across
  • The central in vivo experiment used female myeloid-specific TG2 knockout mice and littermate controls exposed to Ang II for 14 days, with cardiovascular outcomes including systolic blood pressure and aortic stiffness.
  • Myeloid TG2 deletion reduced vascular proinflammatory marker expression and circulating cytokines after Ang II infusion.
  • The paper evidence is preclinical: female mice and in vitro/ex vivo coculture experiments, not human treatment testing.
  • Results are reported for female mice only, limiting generalizability across sexes.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalTest whether myeloid-cell transglutaminase 2 (TG2) causally contributes to angiotensin II (Ang II)-induced hypertension and aortic stiffening/vascular remodeling in female mice.in vivo conditional knockoutExpand

In plain English

In female mice, myeloid-specific deletion of transglutaminase 2 (MyTG2KO) attenuated angiotensin II (Ang II)-induced increases in systolic blood pressure, aortic stiffness, and vascular collagen deposition after a 14-day infusion, relative to littermate controls. The genotype effect was accompanied by reduced vascular proinflammatory markers and circulating cytokines and preservation of the Treg–Th17 balance.

Key findings

  • Myeloid-specific TG2 deletion (MyTG2KO) markedly reduced angiotensin II–induced increases in systolic blood pressure, aortic stiffness, and vascular collagen deposition relative to littermate controls after 14 days of Ang II infusion.
  • Myeloid TG2 deletion was associated with reduced vascular expression of proinflammatory markers and lower circulating cytokines following Ang II infusion.
“Female mice with myeloid-specific deletion of TG2 (MyTG2KO) and littermate controls were infused with Ang II for 14 days.”
What this piece can’t prove
  • Evidence summarized here is based on the abstract; the abstract does not report sample sizes, statistical analyses, or numerical effect sizes.
  • Results are reported for female mice only (sex-specific scope noted in abstract).
  • Abstract does not specify exact methods for measuring aortic stiffness or collagen deposition (histological/biochemical details not provided).

1 further detail could not be confirmed from the summary.

2in vivo animalDetermine whether myeloid TG2 drives Ang II-associated immune imbalance and vascular inflammation in vivo (Treg↓/Th17↑, cytokines/proinflammatory markers), and whether myeloid TG2 deletion attenuates these responses.In vivo Ang II infusion in female myeloid-specific TG2 conditional knockout vs littermate controls; flow cytometry and inflammatory marker assaysExpand

In plain English

In female mice, myeloid-specific deletion of transglutaminase 2 (MyTG2KO) attenuated angiotensin II (Ang II)-associated vascular inflammation and restored Treg–Th17 balance; Ang II decreased Tregs and increased Th17 cells in controls, effects that were reduced in MyTG2KO animals. Deletion of myeloid TG2 also lowered vascular proinflammatory marker expression and circulating cytokines. Coculture experiments with TG2-deficient macrophages supported a role for myeloid TG2 in promoting Th17 and suppressing Treg responses and CD8+ T cell cytotoxicity.

Key findings

  • Myeloid TG2 deletion lowered vascular expression of proinflammatory markers and circulating cytokines in Ang II–infused female mice.markedly reduced (as reported in abstract)
  • Ang II infusion reduced Treg frequency and increased Th17 cells in control mice; these Ang II–associated shifts were attenuated in MyTG2KO mice.Treg decreased / Th17 increased in controls; changes attenuated in MyTG2KO (magnitude not specified)
“Deleting myeloid TG2 lowered vascular expression of proinflammatory markers and circulating cytokines.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3in vitroEstablish a mechanistic cellular explanation using TG2-deficient macrophages in vitro: effects on T cell differentiation/function (promote Treg development, suppress Th17 polarization, reduce CD8+ cytotoxicity) in coculture.in vitro macrophage–T cell cocultureExpand

In plain English

In macrophage–T cell coculture experiments, TG2-deficient macrophages promoted regulatory T cell (Treg) development, suppressed T-helper 17 (Th17) polarization, and reduced CD8+ T cell cytotoxicity.

Key findings

  • TG2-deficient macrophages promoted regulatory T cell (Treg) development in coculture experiments.
  • TG2-deficient macrophages suppressed Th17 polarization in coculture experiments.
“TG2-deficient macrophages promoted Treg development, suppressed Th17 polarization, and decreased CD8+ T cell cytotoxicity in coculture experiments.”
What this piece can’t prove
  • Results derive from in vitro coculture experiments and may not fully generalize to in vivo settings without corroborating mechanistic data or detailed methods.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Europe PMC, Crossref · 33 candidate papers

And 27 more candidates considered.